3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined ...

Sponsor: Boom Broadcast & Media Relations on behalf of LCFAmerica Lung cancer treatment is undergoing a quiet but meaningful ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Ellipses Pharma ("Ellipses"), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for ...

Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase ...

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatm ...

Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...

Background Interstitial lung disease (ILD) is a major pulmonary complication of idiopathic inflammatory myopathy (IIM), where ...

US FDA grants priority review status to Bayer’s sevabertinib for first-line treatment for patients with HER2-mutant non-small cell lung cancer: Berlin Wednesday, May 20, 2026, 1 ...

For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody ...

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.